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Mitochondrial damage has been associated with early steps of cardiac dysfunction in heart
subjected to ischemic stress, oxidative stress and hypertrophy. A common feature for the
mitochondrial deterioration is the loss of the mitochondrial membrane potential (19m)
with the concomitant irreversible opening of the mitochondrial permeability transition pore
(MPTP) which follows the mitochondrial Ca2+ overload, and the subsequent mitochondrial
swelling. We have recently characterized the expression of the Na+/H+ exchanger 1
(mNHE1) in mitochondrial membranes. This surprising observation provided a unique
target for the prevention of the Ca2+-induced MPTP opening, based on the inhibition
of the NHE1m. In this line, inhibition of NHE1m activity and/or reduction of NHE1m
expression decreased the Ca2+-induced mitochondrial swelling and the release of reactive
oxygen species (ROS) in isolated cardiac mitochondria and preserved the 19m in isolated
cardiomyocytes. Mitochondrial NHE1 thus represents a novel target to prevent cardiac
disease, opening new avenues for future research.
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SODIUM/PROTON EXCHANGER (NHE)
Sodium/proton exchangers (NHE) are a family of integral mem-
brane proteins present in most organisms. These transporters
which catalyze the electroneutral exchange of one intracellular
H+ for one extracellular Na+ across membrane along their con-
centrations gradient are crucial for control of intracellular pH
(pHi) and cell volume, and, cell migration and proliferation.
The first NHE isoform to be identified was NHE1, which has
a ubiquitous tissue distribution in mammals (Sardet et al., 1989).
Since its discovery, nine other human isoforms have been iden-
tified (NHE2–NHE10) (Fliegel, 2008; Lee et al., 2008). While
NHE1–NHE6 reside in the plasma membrane or recycling endo-
somes, NHE7–NHE9 are located inside the cell rather than the
plasma membrane (Fliegel, 2008). The NHE10 is expressed in the
surface of osteoclast (Lee et al., 2008).
NHE1 IN THE HEART
NHE1 is the most studied isoform that accumulates preferentially
in microdomains of cells membranes, concentrating along the
basolateral membrane of epithelia (Biemesderfer et al., 1992) and
the intercalated disks and t-tubules of cardiac myocytes (Petrecca
et al., 1999). The sarcolemmal NHE1 is the major Na+ influx
pathway found in the plasma membrane of cardiac cells.
NHE1 is an integral membrane glycoprotein with a pre-
dicted molecular mass of 85 kDa. NHE1 can be separated
into an N-terminal, membrane-associated domain, and a long
C-terminal tail, with both the N-and C-terminal domains being
cytoplasmic (Wakabayashi et al., 1997), (Orlowski and Grinstein,
1997). NHE1 is expressed ubiquitously in mammalian cells,
where it electroneutrally exchanges one intracellular H+ for
one extracellular Na+, thus regulating pHi. The membrane
domain composed of 12 transmembrane regions is associated
with ionic transport (Wakabayashi et al., 1992), and contains the
allosteric H+ sensor site that determines the exquisite sensitivity
of the exchanger to intracellular H+. The cytoplasmic domain is
involved in the regulation of the activity of the exchanger by sev-
eral mechanisms. Removal of the distal region of the cytosolic tail
causes a shift of the pHi sensitivity to the acidic side and an impor-
tant inhibition of NHE1 activation by growth factors (Fliegel
and Karmazyn, 2004). Cytoplasmic tail contains several phospho-
rylation sites and a high affinity and a low-affinity calmodulin
binding sites (Bertrand et al., 1994). The high-affinity binding site
functions as an “autoinhibitory domain” that binds Ca2+-bound
calmodulin and allows activation of the exchanger. Deletion of
this domain constitutively activates NHE1 and mimics elevated
intracellular [Ca2+] (Wakabayashi et al., 1994). In addition, the
cytoplasmic tail contains a binding site for the calcineurin B
homolog protein CHP1, an essential cofactor for NHE1 (Pang
et al., 2001). The exchanger is phosphorylated by different protein
kinases in response to hormone and growth factor stimulation, as
well as sustained acidosis (Sardet et al., 1990, 1991; Haworth et al.,
2003).
Under basal conditions, NHE1 exchanger is relatively qui-
escent and its activity relies only on the extrusion of the H+
produced by the metabolic activity of cells as well as the H+ that
enters the cell through acid-loading mechanisms. However, the
exchanger has an exquisite sensitivity to the increase in intracel-
lular H+ levels and enhances its activity once pHi drops below
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a threshold level by allosterically “sensing” pHi, and by being
phosphorylated or by interacting with some associated proteins,
thus promoting the rapid extrusion of acid (Leem et al., 1999).
NHE1 is constitutively phosphorylated in resting cells, but fur-
ther phosphorylation is induced by several stimuli acting through
G-protein-coupled receptors such as α1-adrenergic receptors,
angiotensin II (Ang II), and endothelin-1 (ET-1). Kinases such
as the Ca2+-/calmodulin-dependent kinase II (Fliegel et al.,
1992), the extracellular signal-regulated kinase (ERK) (Moor and
Fliegel, 1999), 90 kDa ribosomal S6 kinase (p90 rsk) (Takahashi
et al., 1999), p38 mitogen-activated kinase (p38 MAPK) (Khaled
et al., 2001), p160 ROCK (Tominaga et al., 1998), and the
Nck-interacting kinase (NIK) (Yan et al., 2001) putatively phos-
phorylate NHE1 to modulate NHE1 activity. In addition, both
protein kinases C and D are thought to influence NHE1 activity
in response to growth factor and hormone stimulation without
a direct phosphorylation of the exchanger (Fliegel et al., 1992;
Haworth et al., 1999). NHE1 is also susceptible to dephospho-
rylation by protein phosphatases such as PP1 (Misik et al., 2005)
and PP2A (Snabaitis et al., 2006). Carbonic anhydrase II (CAII)
binds to the regulatory cytosolic domain of NHE1 enhancing
its activity. Phosphorylation of the C terminus of NHE1 greatly
increased the binding of CAII. This binding was shown to involve
a protein–protein interaction, suggesting that both proteins con-
stitute a complex. The inhibition of CAII decreased NHE1 activity
significantly (Li et al., 2002).
As previously described, the NHE1, relatively quiescent under
basal conditions, however, becomes highly active during ischemia
in response to intracellular acidosis, leading to NHE1-mediated
Na+ entry into the cell (Karmazyn, 1999a; Karmazyn et al., 1999).
Inhibition of [Na+]i accumulation by increasing NHE activity
and prevention of Ca2+ overload via Na+/Ca2+ exchanger have
been proposed as potential mechanisms of cardioprotection by
NHE1 blockade (Avkiran, 1999). NHE exchanger inhibitors have
proven to protect the heart against ischemia/reperfusion (I/R)
injury (Karmazyn, 1999a,b). Moreover, the positive effect that
NHE1 inhibition exerts on left ventricular systolic function dur-
ing revascularization therapy after acute myocardial infarction
has been documented (Rupprecht et al., 2000). The protection of
the ischemic myocardium by NHE1 inhibition after the onset of
reperfusion has been described (Rohmann et al., 1995; Gumina
et al., 1998; Hurtado and Pierce, 2000). The decrease in myocar-
dial infarct size, through interference with the action of reactive
oxygen species (ROS) generation at the beginning of reperfusion,
has also been reported (Koerner et al., 1991; Tanaka et al., 1994;
McDonald et al., 1999; Sahna et al., 2002). Fantinelli et al. (2006)
described that pharmacological interventions, ROS scavenging
and NHE1 inhibition, when applied together and at their max-
imal effective concentration, did not induce protection further
than that obtained separately by each pharmacologic procedure.
These findings suggest that both interventions act through a com-
mon pathway. The authors proposed that in addition to the effect
of preventing intracellular Na+ increase, NHE1 inhibition by
cariporide decreases ROS-induced damage.
NHE1 activity is controlled by pHi and numerous other fac-
tors, such as hormones, catecholamines, enzymes, and mechan-
ical stimuli, known to be associated with heart disease (Avkiran
and Haworth, 2003; Cingolani et al., 2008; Villa-Abrille et al.,
2010; De Giusti et al., 2011). Furthermore, cardiac expression
of an activated form of NHE1 that lacks the calmodulin-binding
inhibitory domain was sufficient by itself to initiate cardiac hyper-
trophy and heart failure (Nakamura et al., 2008). Constitutively,
active NHE1 leads to pathological changes in activation of
the Ca2+-dependent pro-hypertrophic signaling molecules, cal-
cineurin and CaMKII (Nakamura et al., 2008). Similarly, in heart
over-expression of activated NHE1 was recently found to elicit
specific pathways of gene activation, inducing an increase in
cross-sectional area of cardiomyocyte, interstitial fibrosis, and
depressed cardiac function, in transgenic mice (Xue et al., 2010).
NHE1 AND MITOCHONDRIA
Emerging evidence supports the fact that mitochondrial dys-
function underlies the causes of numerous cardiac diseases (for
review, see Baines, 2010). The mitochondrial death pathway fea-
tures the sequential loss of mitochondrial membrane potential
(19m), which is accompanied by opening of the mitochon-
drial permeability transition pore (MPTP), release of ROS and
diverse toxic proteins which promote the activation of pro-
teolytic activity of caspases (Teshima et al., 2003). When the
MPTP opens, the permeability barrier of the inner membrane
becomes disrupted and causes the free movement of protons
across it, inducing uncoupling of the oxidative phosphoryla-
tion and mitochondria swelling. The MPTP is a large con-
ductance pore thought to be activated by ROS, by increased
mitochondrial Ca2+ levels and by dissipation of the mitochon-
drial 19m (Akao et al., 2003; Javadov and Karmazyn, 2007).
The MPTP opening can be further increased when Ca2+ over-
load is accompanied by oxidative stress, adenine nucleotide
depletion, and elevated phosphate concentrations. Moreover, a
decrease in mitochondrial anion superoxide production induced
by two known enhancers of ROS production, Ang II and
ET-1, upon NHE1 inhibition has been reported (Garciarena
et al., 2008). Furthermore, the increase in ROS production
induced by the opening of the mitochondrial ATP-dependent
K+ channel was abolished by cariporide (Garciarena et al.,
2008).
Studies on the MPTP and its role in reperfusion injury
and cardiac hypertrophy have proven fruitful (Piot et al.,
2008; Halestrap and Pasdois, 2009). Duchen et al. (1993) and
Griffiths and Halestrap (1993) showed that delayed opening of
MPTP by the MPTP inhibitor, cyclosporine A (CsA), protects
ischemic/reperfusion (I/R) injury in perfused rat hearts. Recently,
Piot et al. (2008) reported a decrease in infarct size in patients
with acute myocardial infarction by CsA administered at the time
of reperfusion. Interestingly, a role of mitochondria in determin-
ing cardiac hypertrophy after myocardial infarction has also been
proposed (Karmazyn, 1988; Caldiz et al., 2007; Javadov et al.,
2008, 2009; Cingolani et al., 2010). NHE1 inhibition was one of
the most promising therapeutic strategies for I/R injury based
on experimental animal studies. However controversial results
were obtained using NHE1 inhibitors in clinical trials: cariporide
(GUARDIAN) (Theroux et al., 2000) or EXPEDITION (Mentzer
et al., 2008) and Eniporide (ESCAMI) (Zeymer et al., 2001) (for
review, see Murphy and Allen, 2009). These trials were unable to
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demonstrate a significant reduction in mortality when these com-
pounds were tested in patients after acute myocardial infarction
(Theroux et al., 2000; Zeymer et al., 2001) or were suspended
early due to undesired effects (Mentzer et al., 2008). In a sub-
group of patients who underwent coronary artery bypass graft
surgery and were treated with cariporide, a 25% improvement in
cardiac performance was detected. Similar beneficial effects were
seen in a small trial of 100 patients who received cariporide before
percutaneous coronary angioplasty (Rupprecht et al., 2000).
The related myocardial protective effects induced by CsA and
NHE1 inhibition prompted us to speculate about the possibil-
ity that NHE1 inhibition protects the heart by targeting the
mitochondria (Robin et al., 2007). We recently demonstrated
that reduction of mNHE1 protein expression (shRNA-NHE1)
or specific inhibition of NHE1 (HOE642) at the rat heart
mitochondria significantly reduced the Ca2+-induced mitochon-
drial swelling [Figures 1, 2, modified from Villa-Abrille et al.
(2011)]. Interestingly, HOE642 did not provide additional effect
on Ca2+-induced mitochondrial swelling, in mitochondria with
diminished levels of mNHE1 protein expression, suggesting a
direct involvement of mNHE1 on the susceptibility of the MPTP
for opening following the Ca2+ overload of the mitochondria.
Additionally, the immunosuppressive agent, CsA inhibited the
MPTP opening and mitochondrial swelling to the same extent
as observed in isolated rat heart mitochondria inhibited with
HOE642 or isolated mitochondria with reduced NHE1 expres-
sion [Figures 1, 2, modified from Villa-Abrille et al. (2011)]. We
speculate that a decrease in mitochondrial exchanger function
(or reduced expression by siRNA) should increase H+ concen-
tration on the external side of the MPTP. In this regard, a
prevention of MPTP formation by acidosis after an ischemic
episode has been reported. Thus, accumulation of H+ follow-
ing mNHE1 inhibition or expression reduction should decrease
MPTP opening in heart mitochondria subjected to stress con-
ditions. Though numerous studies (Karmazyn, 1988; Kusumoto
et al., 2001; Wang et al., 2003; Fantinelli et al., 2006) demon-
strated a protective role of NHE1 inhibition I/R injury in the
heart, no mitochondrial effect of NHE1 inhibition has been con-
sidered. However, a report by Ruiz-Meana et al. (2003) drew
attention to this possibility. Furthermore, Aldakkak et al. (2008)
demonstrated that the enhanced activation of NHE with alka-
line pHi during ischemic stress leads to an additional increase
in mitochondrial Ca2+ load, which contributes to greater dete-
rioration of mitochondrial bioenergetics and ROS production
on reperfusion. Authors proved that NHE1 blockade at an alka-
line pH improved the functional recovery after reperfusion,
minimized the increase in mitochondrial [Ca2+], preserved the
mitochondrial redox state, and reduced ROS production. These
data suggested that both sarcolemmal and mitochondrial NHE1
may be involved in promoting mitochondrial Ca2+ loading with
I/R injury. In connection with this, Teshima and collabora-
tors (2003) demonstrated that cariporide protects cardiomyocyte
against cell death induced by oxidative stress, preserving intra-
cellular Na+ and Ca2+ homeostasis and mitochondrial integrity.
FIGURE 1 | Mitochondrial swelling induced by CaCl2. (A) Typical
experiment showing the scattered light absorbance traces of
Ca2+ -induced swelling in response to addition of CaCl2 to heart
mitochondria isolated from rats transduced with shRNA-SCR (SCR,
scrambled, control) in the presence or absence of cariporide (HOE642,
10μM) and Cyclosporine A (CsA, 10mM). Cariporide and Cyclosporine
attenuated Ca2+ -induced mitochondrial swelling and the decrease in light
scattering in mitochondrial suspensions. Cariporide inhibited the decrease
in light scattering in a similar magnitude to CsA. (B) Scheme of a
mitochondrion showing the CaCl2-induced swelling in mitochondria that
expresses scrambled sequence and functional NHE1, and possible
mitochondrial site of action of the cariporide. This inhibitor could act on
different mitochondrial mechanisms, including NHE. They could act
through a decrease in mitochondrial Ca2+ , H+, and 19m affecting the
MPTP formation or altering the sensitivity to those factors to induce
MPTP formation. Modified from Villa-Abrille et al. (2011).
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FIGURE 2 | Mitochondrial swelling induced by CaCl2. (A) Typical
experiment showing the scattered light absorbance traces of
Ca2+ -induced swelling in response to addition of CaCl2 for heart
mitochondria isolated from rats transduced with shRNA-NHE1 in the
presence and absence of cariporide. The shRNA-NHE1 transduction
significantly inhibited Ca2+ -induced mitochondrial swelling compared with
SCR-transduced animals, (as previously shown in Figure 1). Cariporide
and Cyclosporine attenuated the decrease in light scattering in
SCR-transduced rats and did not affect the decrease in light scattering in
shRNA-NHE1-transduced rats. These results indicate that the NHE1
participates in the mechanism by which the Ca2+ induces MPTP opening
and swelling. (B) Scheme showing the absence of mitochondrial swelling
and MPTP opening induced by Ca2+ when NHE1 is silencing. Modified
from Villa-Abrille et al. (2011).
The mitochondrial Ca2+ overload and the mitochondrial 19m
loss induced by oxidative stress were remarkably prevented by
cariporide (Teshima et al., 2003). Additionally, Toda et al. (2007)
demonstrated that the NHE1 inhibitor, cariporide, diminished
the mitochondrial Ca2+ overload and MPTP opening induced by
Na+/K+ ATPase inhibition in isolated cardiomyocytes. Although
these effects were proposed to be secondary to prevention of
the cytosolic increase in Ca2+, more recently a direct mitochon-
drial action of NHE1 inhibitors related to the suppression of the
myocardial superoxide production has been reported (Garciarena
et al., 2008). A “cyclosporine like effect” of NHE1 inhibition was
proposed, but the site of action of those compounds was not iden-
tified (Garciarena et al., 2008). Garciarena et al. (2008) studied
the “anti-ROS effect” of NHE1 inhibitors. The authors ana-
lyzed NADPH oxidase-dependent mitochondrial O2-generation
induced by ANG II or ET-1. The NADPH oxidase-dependent
mitochondrial release of ROS is the basis of the so-called “ROS-
induced ROS release” phenomenon proposed by Zorov et al.
(2000) and Kimura et al. (2005). However, there is no clear evi-
dence that sarcolemmal NADPH oxidase-derived ROS interacts
with the mitochondria. Accordingly, Zhang et al. (2001) using
reconstituted mKATP channels of bovine heart demonstrated that
O2-directly stimulates the opening of these channels. The three
NHE1 inhibitors used by Garciarena et al. (2008) blunted the
increased mitochondrial ROS production and the redox activa-
tion of the kinases, well-known downstream targets of ROS (Sabri
et al., 1998; Rothstein et al., 2002). The authors proposed a direct
mitochondrial effect rather than a scavenging action of NHE1
inhibitors. Additionally, they showed that cariporide blunted not
only the increased O2-production induced by ANG II/ET-1 but
also the production induced by opening the mKATP channel with
diazoxide. A mitochondrial action of NHE1 inhibition secondary
to changes in cytosol was previously suggested by Javadov et al.
(2005). In two previous publications, these authors concluded
that the mitochondrial effect of NHE1 inhibitors is indirect and
possibly mediated by the prevention of cytosolic Ca2+ overload.
Thus, inhibition of the sarcolemmal NHE1 alters intracellular
Na+ concentration and promotes Ca2+ overload (Javadov et al.,
2005, 2008). Accordingly, they did not detect any mitochon-
dria direct effect of the NHE1 inhibitors, and they suggested an
action on MPTP function through glycogen synthase kinase 3-β
(Javadov et al., 2009). We were unable to determine whether
or not under their experimental conditions the effect of NHE1
inhibitors on mitochondrial Ca2+ and/or H+ is prevented.
In 1969, Mitchell and Moyle (1969) proposed the existence
of Na+/H+ exchange in mitochondria. Later, the existence of
two systems capable of catalyze the H+ transport across the
mitochondrial membrane, was described (Garlid et al., 1991).
These systems—the unselective K+/H+ exchanger (KHE), which
catalyzes the transport of virtually all alkali ions in the mitochon-
drion, and the NHE, which selectively transports Na+ or Li+
through mitochondrial membranes—were proposed as the main
cation transporters of the mitochondria (Garlid et al., 1991). In
addition, Garlid et al. (1991) demonstrated in beef heart mito-
chondria that solubilized NHE in the organelle can be purified in
an active state.
In mitochondria, NHE mediates the exchange of matrix Na+
for intermembrane H+ generated by respiration (Garlid, 1988).
Thus, H+ influx in the mitochondrial matrix through the mito-
chondrial NHE would constitute a form of H+ leakage not
coupled to ATP synthesis, which in turn will dissipate the energy
stored as transmitochondrial membrane H+ gradient.
NHE1 is a typical integral membrane protein with 10–12
predicted spanning segments, a long COOH terminus, and an
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NH2-terminal tail that possesses the mitochondrial localization
signal. Previous studies using immunofluorescence and three-
dimensional confocal microscopy techniques demonstrated the
presence of NHE1 in the nuclear membranes isolated from the
aortic vascular smooth muscle and liver of human, rabbit, and rat,
suggesting a possible role of the nuclear NHE1 in the modulation
of intranuclear pH (Bkaily et al., 2004). Our experiments, using
isolated cardiomyocytes or mitochondrial lysates demonstrated
the expression of the NHE1 protein in mitochondria isolated
from rat ventricularmyocardium andmitochondria isolated from
HEK 293 cells transfected with NHE1-HA cDNA (Villa-Abrille
et al., 2011). Besides the expression of NHE1 in the plasma mem-
brane of cardiac cells, we have characterized the expression of
NHE1 in mitochondria of cardiac muscle (Villa-Abrille et al.,
2011) by several different experimental techniques (immunogold
analysis combined with electron microscopy, immunohistochem-
istry combined with confocal microscopy or immunoblot analy-
sis). Accordingly, Javadov et al. (2011) examined the expression
of NHE1 and NHE6 in Percoll-purified rat heart mitochon-
dria by immunoblot analysis and they only observed NHE1 in
the mitochondria fraction (Javadov et al., 2011). Retention of
NHE1 expression in isolated mitochondria subjected to digitonin
allows them to conclude that NHE1 is expressed in the inner
mitochondrial membrane (Javadov et al., 2011).
Dual distribution, at both plasma membrane and mito-
chondria, of others protein like the Na+/Ca+2 exchanger 1-3
(NCX1-3) (Gobbi et al., 2007), and Kv1.3 (Szabo et al., 2005),
Kir6.2 (Garg and Hu, 2007), and Ca+2-activated BK potassium
channels (Siemen et al., 1999), has been previously reported. In
addition, Connexin 43 (Cx43), a constitutive protein that forms
cardiac gap junctions contributing to cell-cell coupling, was also
localized inmitochondria (Boengler et al., 2005, 2009). Cx43 con-
tains four transmembrane domains as well as amino and carboxy
termini located in the cytosol. Cx43 localized in subsarcolem-
mal mitochondria and its carboxy terminus directed toward the
intermembrane space (Boengler et al., 2009).
With the assistance of the RNA interference technique, we
evaluated the function and expression of NHE1 in cardiac tis-
sues. With the objective of knocking down the expression of
NHE1 in the heart, we injected a lentiviral vector expressing
shRNA-NHE1 intramyocardically. The intramyocardial injection
of lentivirus carrying a shRNA-NHE1 (silencing of NHE1) not
only reduced the expression of NHE1 at the level of mitochondria
but also prevented Ca2+-induced swelling of rat heart mitochon-
dria [Figures 1, 2, modified from Villa-Abrille et al. (2011)]. The
silencing of NHE also prevents the development of the slow force
response (Perez et al., 2011). A decrease in mitochondrial NHE
function (or reduced expression by siRNA) should increase H+
concentration in mitochondrial matrix. In connection with this,
the prevention of MPTP formation by acidosis in reperfusion
after ischemia has been reported (Cohen et al., 2007; Rodriguez-
Sinovas et al., 2009). We reported a delay of MPTP formation
in isolated mitochondria by NHE1 inhibition and posttranscrip-
tional NHE1 gene silencing. These findings open a new avenue of
research about the mechanism of protection achieved by NHE1
inhibition in reperfusion injury, cardiac hypertrophy, and heart
failure. The mechanism by which the opening of the MPTP
is prevented at low NHE1 expression is unknown. As previ-
ously described under physiological conditions, the mitochon-
drial NHE introduces cytosolic H+ into the mitochondrial matrix
in exchange for mitochondrial Na+. Therefore, a decrease in
exchanger activity or expression should reduce H+ and increase
Na+ concentration in the mitochondrial matrix and perhaps
increase H+ concentration on the cytosolic side of the MPTP.
The decrease in H+ matrix concentration would favor and not
prevent MPTP formation, but the increase of H+ on the cytoso-
lic side of the MPTP may inhibit pore formation. In connection
with this scenario, the prevention of MPTP formation by aci-
dosis in reperfusion after ischemia has been reported (Cohen
et al., 2007). An increase in mitochondrial Na+ would decrease
the inwardly directed Na+ gradient, affecting the mitochondrial
Na+/Ca2+ exchanger, other factors being constant (Murphy and
Steenbergen, 2008). A decrease in Ca2+ efflux from themitochon-
dria would increase mitochondrial Ca2+ concentration and favor
rather than reduce MPTP formation.
The main objective of this review was to emphasize the pres-
ence of NHE1 in the mitochondrial membrane and its role in
MPTP opening. We are proposing the mitochondrial NHE1 as
a novel target to prevent cardiac disease including I/R injury, car-
diac hypertrophy, and heart failure. However, we could not rule
out the concomitant participation of the sarcolemmal NHE1 in
the protective effects achieved by NHE inhibition.
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